Maternal triptan use during pregnancy is not associated with risk of attention-deficit/hyperactivity disorder in offspring

Référence

Harris GM, Wood M, Ystrom E, Nordeng H. Association of maternal use of triptans during pregnancy with risk of attention-deficit/hyperactivity disorder in offspring. JAMA Network Open 2022;5(6):e2215333.

Sommaire

These investigators analyzed data from multiple Norwegian health registries — including a birth registry, patient registry, and prescription database — from 1999 to 2008. The study sample included women who reported migraines or triptan use during the first trimester or before pregnancy only (n = 10,167) or who filled a triptan prescription during the 6 months before pregnancy. Identification of children with the diagnosis or symptoms of attention-deficit/hyperactivity disorder (ADHD) occurred through chart review and prescription dispensation. In addition, the children of study parents underwent behavioral assessment using a standard ADHD scoring tool at age 5 years. Multiple adjustments occurred for covariates, including maternal age, parity, marital status, education level, income, prepregnancy body mass index, folic acid use, smoking, alcohol use, maternal and paternal ADHD medication use, parental symptoms of anxiety and depression, and parental life satisfaction. Follow-up occurred for a mean of 10.6 years. Prenatal exposure to triptans was not significantly associated with an increased risk of ADHD diagnosis or symptoms.